Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.

Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S.

Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013. Review.

2.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
3.
4.

Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.

Rybak JM, Marx K, Martin CA.

Pharmacotherapy. 2014 Nov;34(11):1198-208. doi: 10.1002/phar.1491. Epub 2014 Sep 30. Review.

PMID:
25266820
5.

Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.

Chahine EB, Sucher AJ, Knutsen SD.

Consult Pharm. 2015 Jul;30(7):386-94. doi: 10.4140/TCP.n.2015.386. Review.

PMID:
26173190
6.

Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.

Burdette SD, Trotman R.

Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Epub 2015 Jun 23. Review.

PMID:
26105167
7.

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR.

Antimicrob Agents Chemother. 2011 Feb;55(2):583-92. doi: 10.1128/AAC.00076-10. Epub 2010 Nov 29.

8.

Tedizolid: a new oxazolidinone antimicrobial.

Kisgen JJ, Mansour H, Unger NR, Childs LM.

Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482. Review.

PMID:
24688035
9.

Tedizolid for treatment of acute bacterial skin and skin structure infections.

Hui Y, Xiaoju L.

Expert Rev Anti Infect Ther. 2015;13(9):1051-60. doi: 10.1586/14787210.2015.1073107. Epub 2015 Jul 27. Review.

PMID:
26211946
10.

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Prokocimer P, De Anda C, Fang E, Mehra P, Das A.

JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.

PMID:
23403680
11.

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.

12.

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.

Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G.

Ann Clin Microbiol Antimicrob. 2014 Sep 20;13:46. doi: 10.1186/s12941-014-0046-0.

13.

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P.

Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.

PMID:
24909499
14.

Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.

Douros A, Grabowski K, Stahlmann R.

Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2015;11(12):v.

PMID:
26457865
15.

Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.

Choi S, Im W, Bartizal K.

Antimicrob Agents Chemother. 2012 Sep;56(9):4713-7. doi: 10.1128/AAC.00346-12. Epub 2012 Jun 19.

16.

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.

Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7. doi: 10.1093/cid/cit618. Review.

17.

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.

Hall RG 2nd, Michaels HN.

Infect Drug Resist. 2015 Apr 22;8:75-82. doi: 10.2147/IDR.S56691. eCollection 2015. Review.

18.

Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.

Thomson KS, Goering RV.

Antimicrob Agents Chemother. 2013 Jun;57(6):2892-5. doi: 10.1128/AAC.00274-13. Epub 2013 Apr 9.

19.

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P.

Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22.

20.

Tedizolid Phosphate: a Next-Generation Oxazolidinone.

Rybak JM, Roberts K.

Infect Dis Ther. 2015 Feb 24. [Epub ahead of print]

Items per page

Supplemental Content

Write to the Help Desk